Investigating low vulnerability of posterior eye segment to SARS-CoV-2

Video
Conference|ARVO

Dr Steffen E. Künzel discusses the key points of his research presentation regarding low vulnerability of the posterior eye segment to SARS-CoV-2 infection.

Dr Steffen E. Künzel, from the Department of Ophthalmology Charité University Medicine Berlin, Berlin, Germany, discusses the key points of his research presentation on low vulnerability of the posterior eye segment to SARS-CoV-2 infection during the virtual 2021 ARVO meeting.

See more ARVO content

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Related Content
ARVO President Srinivas Sadda, MD, FARVO, leads a preview of the 2025 meeting. Image provided courtesy of the Association for Research in Vision and Ophthalmology (ARVO).

Recap: The Association for Research in Vision and Ophthalmology takes Seattle

Hattie Hayes
June 10th 2024
Article

ARVO attendees took a deep dive into trends and explored the near future of vision science

A single tear on a person's face. Image credit: ©Chepko Danil – stock.adobe.com

ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease

Lynda Charters
May 7th 2024
Article

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

A young girl undergoes an eye exam. Image credit: ©Alexis S/peopleimages.com – stock.adobe.com

ARVO 2024: Children with CVI experience lower vision-specific quality of life, study results indicate

Lynda Charters
May 6th 2024
Article

Investigators say children with cortical/cerebral visual impairment experience markedly lower vision-specific quality of life

A child has their blood sugar tested using a digital glucometer. Image credit: ©Africa Studio – stock.adobe.com

ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes

Lynda Charters
May 5th 2024
Article

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

A group of children run outside. Image credit: ©JackF – stock.adobe.com

ARVO 2024: CHAMP phase 3 trial shows myopia controlled by low-dose atropine 0.01% over 4-year course

Lynda Charters
May 5th 2024
Article

This study also investigated the development of myopia rebound when dosing was discontinued

Susana Chung, OD, PhD, talks about her ARVO presentation titled "How similar is reading with central vision loss to reading in normal peripheral vision?"

ARVO 2024: New research indicates the need for a new approach to central vision loss

Hattie Hayes;Sydney M Crago
May 5th 2024
Article

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

© 2024 MJH Life Sciences

All rights reserved.